Trials
1 active
4 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Rheumatoid Arthritis
- Main trialPhase 2
- “Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA). This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab…”In the company’s words, NCT06972446 on ClinicalTrials.gov
- Other names
- Ravaglimab · ABBV-323
Other drugs for Rheumatoid Arthritis
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up1
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2027 | A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | |
| Phase 2Completed | 5 Apr 2021 | A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | |
| Phase 2Withdrawn | 15 Apr 2022 | An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS) | |
| Phase 1Completed | 8 Oct 2024 | A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026